Benzimidazole

Benzimidazole

SCHEMBL5404384

NN.c1ccc2[nH]cnc2c1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.52
KDM4E B2RXH2 6/20 0.50
MAPT P10636 2/20 0.50
RAD52 P43351 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
PDPK1 O15530 1/20 0.47
CA12 O43570 1/20 0.47
PARP1 P09874 1/20 0.47
ALOX15 P16050 1/20 0.47
CA9 Q16790 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
ALDH1A1 P00352 6/20 0.45
TDP1 Q9NUW8 2/20 0.45
APEX1 P27695 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
HPGD P15428 3/20 0.44
RAB9A P51151 2/20 0.44
QPCT Q16769 2/20 0.44
QPCTL Q9NXS2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzimidazole SCHEMBL29408372 0.95
Benzimidazole SCHEMBL29358377 0.95
Benzimidazole SCHEMBL461969 0.95 SMN1; SMN2 (0.50) PRKCIKDM4EMAPTRAD52SMN1; SMN2
Benzimidazole SCHEMBL6009 0.95
Benzimidazole SCHEMBL10931770 0.95 SMN1; SMN2 (0.50) PRKCIKDM4EMAPTRAD52SMN1; SMN2
Benzimidazole SCHEMBL2334176 0.93 PRKCI (0.50) PRKCIKDM4EMAPTRAD52SMN1; SMN2
Benzimidazole SCHEMBL23673327 0.93 SMN1; SMN2 (0.48) PRKCIKDM4EMAPTRAD52SMN1; SMN2
Benzimidazole SCHEMBL21046391 0.93
Benzimidazole SCHEMBL4883891 0.93 KDM4E (0.48) PRKCIKDM4EMAPTRAD52SMN1; SMN2
Benzimidazole SCHEMBL22551123 0.93 SMN1; SMN2 (0.48) PRKCIKDM4EMAPTRAD52SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7244847-B2 Benzimidazole compounds ISIS PHARMACEUTICALS, INC. (US) 2007-07-17 US disclosed
WO-2004047769-A2 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIBACTERIALS ISIS PHARMACEUTICALS, INC. (US) 2004-06-10 WO disclosed
US-20030187258-A1 Novel benzimidazole compounds US GOVERNMENT - SECRETARY FOR THE ARMY 2003-10-02 US disclosed
WO-2003066622-A1 NOVEL BENZIMIDAZOLE COMPOUNDS ISIS, PHARMACEUTICALS (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187258-A1 Novel benzimidazole compounds BRD4, BRI3BP, BRD3 PRKCI 2292/4885KDM4E 835/4885MAPT 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.